Cargando…
Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine
BACKGROUND: Dendritic cells (DCs) are antigen-presenting cells that play a pivotal role in adaptive cell-mediated immunity by priming and activating T cells against specific tumour and pathogenic antigens. Methotrexate (MTX), a folate derivative, functions as an immunoregulatory agent. However, the...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841859/ https://www.ncbi.nlm.nih.gov/pubmed/33613696 http://dx.doi.org/10.1177/1758835920987056 |
_version_ | 1783643892349927424 |
---|---|
author | Shi, Gao-Na Hu, Min Chen, Chengjuan Fu, Junmin Shao, Shuai Zhou, Yu Wu, Lei Zhang, Tiantai |
author_facet | Shi, Gao-Na Hu, Min Chen, Chengjuan Fu, Junmin Shao, Shuai Zhou, Yu Wu, Lei Zhang, Tiantai |
author_sort | Shi, Gao-Na |
collection | PubMed |
description | BACKGROUND: Dendritic cells (DCs) are antigen-presenting cells that play a pivotal role in adaptive cell-mediated immunity by priming and activating T cells against specific tumour and pathogenic antigens. Methotrexate (MTX), a folate derivative, functions as an immunoregulatory agent. However, the possible effect of MTX on tumour antigen-loaded DCs has not yet been investigated. METHODS: We analysed the effect of MTX on the maturation and function of DCs along with tumour cell lysates (TCLs). Using bone marrow-derived DCs, we investigated the effect of MTX combined TCL-loaded DCs on T cells priming and proliferation. We also tested the anti-tumour immune effect on DCs when treated with MTX and/or TCL in vivo. RESULTS: MTX combined with TCL not only enhanced DC maturation and stimulated cytokine release but also promoted CD8(+) T cell activation and proliferation. The latter was associated with increased tumour antigen uptake and cross-presentation to T cells. Mechanistically, DC maturation and antigen presentation were partly modulated by NLRP3 inflammasome activation. Furthermore, immunisation of mice with MTX and TCL-pulsed DCs before a tumour challenge significantly delayed tumour onset and retarded its growth. This protective effect was due to priming of IFN-γ releasing CD8(+) T cells and enhanced killing of tumour cells by cytotoxic T lymphocytes isolated from these immunised mice. CONCLUSION: MTX can function as a potent adjuvant in DC vaccines by increasing antigen presentation and T cell priming. Our findings provide a new strategy for the application of DC-based anti-tumour immunotherapy. |
format | Online Article Text |
id | pubmed-7841859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-78418592021-02-19 Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine Shi, Gao-Na Hu, Min Chen, Chengjuan Fu, Junmin Shao, Shuai Zhou, Yu Wu, Lei Zhang, Tiantai Ther Adv Med Oncol Original Research BACKGROUND: Dendritic cells (DCs) are antigen-presenting cells that play a pivotal role in adaptive cell-mediated immunity by priming and activating T cells against specific tumour and pathogenic antigens. Methotrexate (MTX), a folate derivative, functions as an immunoregulatory agent. However, the possible effect of MTX on tumour antigen-loaded DCs has not yet been investigated. METHODS: We analysed the effect of MTX on the maturation and function of DCs along with tumour cell lysates (TCLs). Using bone marrow-derived DCs, we investigated the effect of MTX combined TCL-loaded DCs on T cells priming and proliferation. We also tested the anti-tumour immune effect on DCs when treated with MTX and/or TCL in vivo. RESULTS: MTX combined with TCL not only enhanced DC maturation and stimulated cytokine release but also promoted CD8(+) T cell activation and proliferation. The latter was associated with increased tumour antigen uptake and cross-presentation to T cells. Mechanistically, DC maturation and antigen presentation were partly modulated by NLRP3 inflammasome activation. Furthermore, immunisation of mice with MTX and TCL-pulsed DCs before a tumour challenge significantly delayed tumour onset and retarded its growth. This protective effect was due to priming of IFN-γ releasing CD8(+) T cells and enhanced killing of tumour cells by cytotoxic T lymphocytes isolated from these immunised mice. CONCLUSION: MTX can function as a potent adjuvant in DC vaccines by increasing antigen presentation and T cell priming. Our findings provide a new strategy for the application of DC-based anti-tumour immunotherapy. SAGE Publications 2021-01-21 /pmc/articles/PMC7841859/ /pubmed/33613696 http://dx.doi.org/10.1177/1758835920987056 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Shi, Gao-Na Hu, Min Chen, Chengjuan Fu, Junmin Shao, Shuai Zhou, Yu Wu, Lei Zhang, Tiantai Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine |
title | Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine |
title_full | Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine |
title_fullStr | Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine |
title_full_unstemmed | Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine |
title_short | Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine |
title_sort | methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through nlrp3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841859/ https://www.ncbi.nlm.nih.gov/pubmed/33613696 http://dx.doi.org/10.1177/1758835920987056 |
work_keys_str_mv | AT shigaona methotrexateenhancesantigenpresentationandmaturationoftumourantigenloadeddendriticcellsthroughnlrp3inflammasomeactivationastrategyfordendriticcellbasedcancervaccine AT humin methotrexateenhancesantigenpresentationandmaturationoftumourantigenloadeddendriticcellsthroughnlrp3inflammasomeactivationastrategyfordendriticcellbasedcancervaccine AT chenchengjuan methotrexateenhancesantigenpresentationandmaturationoftumourantigenloadeddendriticcellsthroughnlrp3inflammasomeactivationastrategyfordendriticcellbasedcancervaccine AT fujunmin methotrexateenhancesantigenpresentationandmaturationoftumourantigenloadeddendriticcellsthroughnlrp3inflammasomeactivationastrategyfordendriticcellbasedcancervaccine AT shaoshuai methotrexateenhancesantigenpresentationandmaturationoftumourantigenloadeddendriticcellsthroughnlrp3inflammasomeactivationastrategyfordendriticcellbasedcancervaccine AT zhouyu methotrexateenhancesantigenpresentationandmaturationoftumourantigenloadeddendriticcellsthroughnlrp3inflammasomeactivationastrategyfordendriticcellbasedcancervaccine AT wulei methotrexateenhancesantigenpresentationandmaturationoftumourantigenloadeddendriticcellsthroughnlrp3inflammasomeactivationastrategyfordendriticcellbasedcancervaccine AT zhangtiantai methotrexateenhancesantigenpresentationandmaturationoftumourantigenloadeddendriticcellsthroughnlrp3inflammasomeactivationastrategyfordendriticcellbasedcancervaccine |